MX2019001084A - Variantes de gpr156 y usos de estas. - Google Patents

Variantes de gpr156 y usos de estas.

Info

Publication number
MX2019001084A
MX2019001084A MX2019001084A MX2019001084A MX2019001084A MX 2019001084 A MX2019001084 A MX 2019001084A MX 2019001084 A MX2019001084 A MX 2019001084A MX 2019001084 A MX2019001084 A MX 2019001084A MX 2019001084 A MX2019001084 A MX 2019001084A
Authority
MX
Mexico
Prior art keywords
gpr156
aspartic acid
disclosure
protein
alterations
Prior art date
Application number
MX2019001084A
Other languages
English (en)
Spanish (es)
Inventor
Gonzaga-Jauregui Claudia
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2019001084A publication Critical patent/MX2019001084A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
MX2019001084A 2016-07-28 2017-07-28 Variantes de gpr156 y usos de estas. MX2019001084A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662367973P 2016-07-28 2016-07-28
PCT/US2017/044321 WO2018022967A1 (en) 2016-07-28 2017-07-28 Gpr156 variants and uses thereof

Publications (1)

Publication Number Publication Date
MX2019001084A true MX2019001084A (es) 2019-06-10

Family

ID=59649989

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001084A MX2019001084A (es) 2016-07-28 2017-07-28 Variantes de gpr156 y usos de estas.
MX2024013403A MX2024013403A (es) 2016-07-28 2019-01-25 Variantes de gpr156 y usos de estas

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024013403A MX2024013403A (es) 2016-07-28 2019-01-25 Variantes de gpr156 y usos de estas

Country Status (13)

Country Link
US (4) US10266582B2 (enExample)
EP (2) EP4230648A3 (enExample)
JP (2) JP7556688B2 (enExample)
KR (2) KR102661616B1 (enExample)
CN (1) CN109563516B (enExample)
AU (1) AU2017302611B2 (enExample)
CA (1) CA3032124A1 (enExample)
DK (1) DK3491014T5 (enExample)
IL (1) IL264473A (enExample)
MX (2) MX2019001084A (enExample)
NZ (1) NZ751010A (enExample)
SG (1) SG11201900738YA (enExample)
WO (1) WO2018022967A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4230648A3 (en) * 2016-07-28 2023-10-18 Regeneron Pharmaceuticals, Inc. Gpr156 variants and uses thereof
SG11202001754RA (en) 2017-09-06 2020-03-30 Regeneron Pharma Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
AU2020209184A1 (en) * 2019-01-17 2021-07-08 Regeneron Pharmaceuticals, Inc. A rodent model of mood disorders

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
DE69425890D1 (de) 1993-06-04 2000-10-19 Us Health Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
JPH10503934A (ja) 1994-08-09 1998-04-14 ノバルティス アクチエンゲゼルシャフト 抗腫瘍性アンチセンスオリゴヌクレオチド
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
WO1997014709A1 (en) 1995-10-13 1997-04-24 F. Hoffmann-La Roche Ag Antisense oligomers
CA2236825A1 (en) 1995-11-21 1997-05-29 Icn Pharmaceuticals, Inc. Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor
US5998602A (en) 1996-02-15 1999-12-07 The Cleveland Clinic Fouindation And Government RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
AU6343400A (en) * 1999-07-09 2001-01-30 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
AU2001255397A1 (en) * 2000-04-18 2001-10-30 Genaissance Pharmaceuticals, Inc. Haplotypes of the ugt1a1 gene
JP2006513702A (ja) 2002-09-09 2006-04-27 ヌラ インコーポレーティッド Gタンパク質共役受容体およびその使用
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
EP1745018A1 (en) * 2004-04-29 2007-01-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
EP2091556B1 (en) 2006-11-15 2018-07-25 Omeros Corporation Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease
AU2013262709A1 (en) * 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
MY189533A (en) 2012-05-25 2022-02-16 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
AU2013355214B2 (en) 2012-12-06 2017-06-15 Sigma-Aldrich Co. Llc Crispr-based genome modification and regulation
SG11201805112WA (en) * 2015-12-21 2018-07-30 Bayer Oy A method of manufacturing a vaginal ring
EP4230648A3 (en) 2016-07-28 2023-10-18 Regeneron Pharmaceuticals, Inc. Gpr156 variants and uses thereof

Also Published As

Publication number Publication date
AU2017302611A1 (en) 2019-03-14
US10266582B2 (en) 2019-04-23
DK3491014T3 (da) 2023-05-30
EP3491014B1 (en) 2023-04-05
CN109563516B (zh) 2023-10-27
US11155598B2 (en) 2021-10-26
KR102661616B1 (ko) 2024-04-30
CA3032124A1 (en) 2018-02-01
WO2018022967A1 (en) 2018-02-01
CN109563516A (zh) 2019-04-02
EP4230648A3 (en) 2023-10-18
US20190202891A1 (en) 2019-07-04
US20200231651A1 (en) 2020-07-23
NZ751010A (en) 2024-11-29
JP2023071704A (ja) 2023-05-23
US10562953B2 (en) 2020-02-18
EP3491014A1 (en) 2019-06-05
KR20190034532A (ko) 2019-04-02
AU2017302611B2 (en) 2021-12-09
IL264473A (en) 2019-02-28
KR20240027874A (ko) 2024-03-04
SG11201900738YA (en) 2019-02-27
JP2019527229A (ja) 2019-09-26
MX2024013403A (es) 2024-12-06
US20220073589A1 (en) 2022-03-10
DK3491014T5 (da) 2024-09-02
JP7556688B2 (ja) 2024-09-26
US20180030114A1 (en) 2018-02-01
EP4230648A2 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
MX2024013403A (es) Variantes de gpr156 y usos de estas
PH12019500596B1 (en) Recombinant binding proteins and their use
PH12018502361B1 (en) Gdf15 fusion proteins and uses thereof
PH12019500209A1 (en) Methods and compositions for gene expression in plants
SG10201906673WA (en) Artificial nucleic acid molecules
HRP20231707T1 (hr) Životinje koje nisu ljudi, koje sadrže humanizirani gen iz diferencijacijske skupine 47
EA201691111A1 (ru) Химерные белки фактора viii и их применение
RU2020122439A (ru) Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
HRP20240855T1 (hr) Neljudske životinje koje imaju humanizirani gen cd274 iz diferencijacijske skupine
SG10201808565QA (en) Fgfr fusions
BR112015002280A2 (pt) produção de gado resistente a vfa por substituição de alelo
MX2018011425A (es) Construcciones de anticuerpos de adn y método para utilizarlas.
JP2019500414A5 (enExample)
CY1123793T1 (el) Γονιδιακη θεραπεια rpgr για μελαγχρωστικη αμφιβληστροειδοπαθεια
MX2022010959A (es) Terapia genica para trastornos oculares.
CY1119976T1 (el) Μιμητικα καλσιτονινης για την αντιμετωπιση ασθενειων και διαταραχων
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
MX382218B (es) Variantes de lipasa y polinucleotidos que las codifican.
NZ752941A (en) Frataxin expression constructs
NZ729735A (en) Biosensor based on gβυ-interacting proteins to monitor g-protein activation
MX2021002135A (es) Secuencia génica de gtpasa similar a dineína mitocondrial de tipo ii humana recombinante y usos de esta.
NZ724196A (en) Uti fusion proteins
CY1116486T1 (el) Βελτιωμενο συστημα εκφρασης ανθρωπινης μακρας πεντραξινης 3 και χρησεις αυτης
MX2015006599A (es) Secuencias de ácidos desoxirribonucleicos sintéticos y proteinas recombinantes heterólogas de la hemaglutinina del virus influenza expresadas en cloroplasto de chlamydomonas reinhardtii y su uso en vacunas.
WO2015132397A3 (en) Mitochondrial preproteins as markers for alzheimer's disease